Twist Bioscience Co. (NASDAQ:TWST) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been given an average rating of “Moderate Buy” by the ten ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $51.90.

TWST has been the topic of a number of analyst reports. Evercore ISI increased their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Wolfe Research assumed coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Barclays decreased their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Robert W. Baird raised their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. Finally, Scotiabank boosted their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 19th.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 4,160 shares of Twist Bioscience stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $185,536.00. Following the sale, the chief financial officer now owns 89,237 shares in the company, valued at $3,979,970.20. The trade was a 4.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Paula Green sold 1,057 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $43,928.92. Following the completion of the sale, the senior vice president now directly owns 121,013 shares in the company, valued at $5,029,300.28. This trade represents a 0.87 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,640 shares of company stock worth $4,123,772. 3.92% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Principal Financial Group Inc. raised its position in Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock worth $9,301,000 after purchasing an additional 82,953 shares in the last quarter. Oddo BHF Asset Management Sas acquired a new position in shares of Twist Bioscience in the 3rd quarter worth approximately $3,302,000. Beaird Harris Wealth Management LLC acquired a new position in shares of Twist Bioscience in the 3rd quarter worth approximately $95,000. Franklin Resources Inc. lifted its position in shares of Twist Bioscience by 3.4% during the 3rd quarter. Franklin Resources Inc. now owns 252,064 shares of the company’s stock worth $11,756,000 after buying an additional 8,308 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience in the 3rd quarter valued at $34,000.

Twist Bioscience Trading Down 1.9 %

Shares of NASDAQ:TWST opened at $42.75 on Wednesday. Twist Bioscience has a 1 year low of $27.41 and a 1 year high of $60.90. The firm has a fifty day moving average price of $46.43 and a 200 day moving average price of $46.38. The stock has a market capitalization of $2.54 billion, a PE ratio of -11.88 and a beta of 1.85.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.